Caracterización química del aceite de barú y su subproducto de la región noroeste de Minas Gerais, Brasil

This study investigated baru oil and partially defatted baru flour from the northwest region of Minas Gerais, Brazil. The physicochemical characterization of the oil was made by determining the fatty acid profile using gas chromatography, lutein, and α- and β- carotenes by means of high-performance liquid chromatography, and total carotenoids by spectrophotometry. The flour was analyzed for its chemical composition, fiber, and mineral contents. Baru oil presented excellent quality parameters and high contents in unsaturated fatty acids and carotenoids. The flour showed relevant levels of proteins, lipids, and dietary fiber, in addition to having representative mineral contents for food such as manganese, magnesium, and copper. Thus, baru oil and the by-product of its extraction offer a rich chemical composition, and their application may add nutritional value to foods in addition to reducing negative environmental impacts.En este estudio se investigó el aceite de barú y la harina de barú parcialmente desengrasada de la región noroeste de Minas Gerais, Brasil. La caracterización físico-química del aceite se realizó mediante la determinación del perfil de ácidos grasos mediante cromatografía de gases, luteína y α- y β- carotenos mediante cromatografía líquida de alta resolución y carotenoides totales mediante espectrofotometría. En la harina se analizó su composición química, fibra y contenido mineral. El aceite de barú tiene excelentes parámetros de calidad, un buen contenido de ácidos grasos insaturados y carotenoides. La harina presentó niveles relevantes de proteínas, lípidos y fibra dietética, además de tener un contenido representativo de minerales para la alimentación, como manganeso, magnesio y cobre. Así, el aceite de baru y el subproducto de su extracción tienen riqueza en su composición química y su aplicación puede agregar valor nutricional a los alimentos, además de reducir los impactos ambientales

Studying How Health Literacy Influences Attention during Online Information Seeking

Health literacy affects how people understand health information and, therefore, should be considered by search engines in health searches. In this work, we analyze how the level of health literacy is related to the eye movements of users searching the web for health information. We performed a user study with 30 participants that were asked to search online in the context of three work task situations defined by the authors. Their eye interactions with the Search Results Page and the Result Pages were logged using an eye-tracker and later analyzed. When searching online for health information, people with adequate health literacy spend more time and have more fixations on Search Result Pages. In this type of page, they also pay more attention to the results' hyperlink and snippet and click in more results too. In Result Pages, adequate health literacy users spend more time analyzing textual content than people with lower health literacy. We found statistical differences in terms of clicks, fixations, and time spent that could be used as a starting point for further research. That we know of, this is the first work to use an eye-tracker to explore how users with different health literacy search online for health-related information. As traditional instruments are too intrusive to be used by search engines, an automatic prediction of health literacy would be very useful for this type of system

Poor disability outcomes in the management of Low Back Pain patients in Portugal

Trabalho apresentado em 10th Interdisciplinary World Congress on Low Back & Pelvic Girdle Pain, 28-31 de outubro 2019, Antuérpia, BélgicaN/

Illusions of general relativity in Brans-Dicke gravity

Contrary to common belief, the standard tenet of Brans-Dicke theory reducing to general relativity when omega tends to infinity is false if the trace of the matter energy-momentum tensor vanishes. The issue is clarified in a new approach using conformal transformations. The otherwise unaccountable limiting behavior of Brans-Dicke gravity is easily understood in terms of the conformal invariance of the theory when the sources of gravity have radiation-like properties. The rigorous computation of the asymptotic behavior of the Brans-Dicke scalar field is straightforward in this new approach.Comment: 16 pages, LaTeX, to appear in Physical Review

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial

PD1 expression in CD4+ and CD8+ T cells is increased after treatment in multiple myeloma patients with persistent disease. The GEM-Pembresid trial analyzed the efficacy and safety of pembrolizumab as consolidation in patients achieving at least very good partial response but with persistent measurable disease after first- or second-line treatment. Moreover, the characteristics of the immune system were investigated to identify potential biomarkers of response to pembrolizumab. One out of the 17 evaluable patients showed a decrease in the amount of M-protein, although a potential late effect of high-dose melphalan could not be ruled out. Fourteen adverse events were considered related to pembrolizumab, two of which (G3 diarrhea and G2 pneumonitis) prompted treatment discontinuation and all resolving without sequelae. Interestingly, pembrolizumab induced a decrease in the percentage of NK cells at cycle 3, due to the reduction of the circulating and adaptive subsets (0.615 vs. 0.43, p = 0.007; 1.12 vs. 0.86, p = 0.02). In the early progressors, a significantly lower expression of PD1 in CD8+ effector memory T cells (MFI 1327 vs. 926, p = 0.03) was observed. In conclusion, pembrolizumab used as consolidation monotherapy shows an acceptable toxicity profile but did not improve responses in this MM patient population. The trial was registered at clinicaltrials.gov with identifier NCT02636010 and with EUDRACT number 2015-003359-23.This study was funded by Fundación Ramón Areces (FRA 16/003). T.P. is supported by a grant from the AECC (INVES18043PAIN). This study received financial support from Merck Sharp & Dohme of Spain, a subsidiary of Merck & Co., Inc., Whitehouse Station, New Jersey, USA

Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis

Immunoglobulin light-chain amyloidosis (AL) and multiple myeloma (MM) are 2 distinct monoclonal gammopathies that involve the same cellular compartment: clonal plasma cells (PCs). Despite the fact that knowledge about MM PC biology has significantly increased in the last decade, the same does not apply for AL. Here, we used an integrative phenotypic, molecular, and genomic approach to study clonal PCs from 24 newly diagnosed patients with AL. Through principal-component-analysis, we demonstrated highly overlapping phenotypic profiles between AL and both monoclonal gammopathy of undetermined significance and MM PCs. However, in contrast to MM, highly purified fluorescence-activated cell-sorted clonal PCs from AL (n = 9) showed almost normal transcriptome, with only 38 deregulated genes vs normal PCs; these included a few tumor-suppressor (CDH1, RCAN) and proapoptotic (GLIPR1, FAS) genes. Notwithstanding, clonal PCs in AL (n=11) were genomically unstable, with a median of 9 copy number alterations (CNAs) per case, many of such CNAs being similar to those found in MM. Whole-exome sequencing (WES) performed in 5 AL patients revealed a median of 15 nonrecurrent mutations per case. Altogether, our results show that in the absence of a unifying mutation by WES, clonal PCs in AL display phenotypic and CNA profiles similar to MM, but their transcriptome is remarkably similar to that of normal PCs

Pembrolizumab as consolidation strategy in patients with multiple myeloma: Results of the GEM-Pembresid clinical trial

PD1 expression in CD4+ and CD8+ T cells is increased after treatment in multiple myeloma patients with persistent disease. The GEM-Pembresid trial analyzed the efficacy and safety of pembrolizumab as consolidation in patients achieving at least very good partial response but with persistent measurable disease after first- or second-line treatment. Moreover, the characteristics of the immune system were investigated to identify potential biomarkers of response to pembrolizumab. One out of the 17 evaluable patients showed a decrease in the amount of M-protein, although a potential late effect of high-dose melphalan could not be ruled out. Fourteen adverse events were considered related to pembrolizumab, two of which (G3 diarrhea and G2 pneumonitis) prompted treatment discontinuation and all resolving without sequelae. Interestingly, pembrolizumab induced a decrease in the percentage of NK cells at cycle 3, due to the reduction of the circulating and adaptive subsets (0.615 vs. 0.43, p = 0.007; 1.12 vs. 0.86, p = 0.02). In the early progressors, a significantly lower expression of PD1 in CD8+ effector memory T cells (MFI 1327 vs. 926, p = 0.03) was observed. In conclusion, pembrolizumab used as consolidation monotherapy shows an acceptable toxicity profile but did not improve responses in this MM patient population. The trial was registered at clinicaltrials.gov with identifier NCT02636010 and with EUDRACT number 2015-003359-23